Commit Biologics, a Copenhagen-based biotech startup, announced that it has raised €54 million ($60 million) in Seed funding aimed at advancing treatments for cancer and autoimmune diseases. This substantial investment will enable the company to bring its initial drug candidate closer to clinical trials, marking a significant step in its development.
The funding round was led by Ackermans & van Haaren, with additional contributions from new investors AbbVie Ventures and M Ventures, along with existing backers Bioqube Ventures, Korys, and Novo Holdings. CEO Dr. Thomas L. F. Montgomery Andresen emphasized the pride in having strong financial support, indicating the importance this financing holds for their future in immunotherapy.
With this financing secured, Commit Biologics plans to advance their drug candidate COM002 into clinical trials, establishing a foundation for further developments in complement-powered immunotherapy.
